

Welcome to our first newsletter in 2011

Editorial

- **Welcome**
- **New releases:**
Navisuite 5.1
Oncentra Prostate V4.0
- **Abstracts of:**
Prosoma User Meeting
in Birmingham

Prostate Salvage Congress,
Heidelberg

Upcoming events

Meet MedCom on your visit to one of the following events:

- **EAU 2011**
March 18-22, Vienna Austria: Annual Congress of the European Association of Urology
- **PTCOG 2011**
May 8-14, Philadelphia PA: Platform for education, awareness and understanding of the particle beam therapy
- **DEGRO 2011**
June 2-11, Wiesbaden Germany: 17. Jahreskongress der Deutschen Gesellschaft für Radioonkologie

The past period was of paramount importance for MedCom. Following our strategy to amplify and diversify our product portfolio in the oncological treatment field, we succeeded to introduce two brand-new products underlining our determination towards this goal:

The new **Oncentra® Prostate** System has been developed in cooperation with our long-term partner Pi-medical Ltd and is distributed exclusively and world-wide by Nucletron, the dominating international player in brachytherapy. The new Oncentra Prostate is the only existing integrated solution offering simply everything on one hand: afterloading, seeds and ultrasound imaging all integrated in one cart.

BiopSee® is the first-of-its-kind system for a holistic prostate biopsy approach. BiopSee® incorporates our 15 years experience in imaging and prostate therapy and implements transperineal, stereotactic navigated biopsies. The system fuses (overlays) pre-operative imaging such as multiparametric MRI, PET/SPECT etc. with intraoperative 3D-ultrasound for guiding the biopsy needles mm-exactly on the suspicious areas. Due to the results to be published by the first system users within the next weeks, we are convinced that this approach will soon have a major impact on the urology practice.




Prof. Georgios Sakas, CEO

Salvage Congress Heidelberg

MedCom participated and sponsored the recent interdisciplinary symposium on prostate cancer recurrence and salvage therapy. The event was held on 28th and 29th January in Heidelberg in the locations of the German Cancer Research Centre (DKFZ).

The meeting gathered 22 speakers and ca. 200 participants from different medical fields. MedCom presented its latest BiopSee® developments, elaborated in cooperation with PI medical: The final version of the device cart was shown along with the mechanical stepper, the "one hole template" and the ultrasound probe, all custom-made components. Many participants could test hands-on the system in our booth. Due to the interdisciplinary character of the meeting, it was our pleasure to demonstrate to different users the significant benefits of our approach of combining arbitrary preoperative DICOM diagnostic datasets (coming from the radiology department) together with intraoperatively gathered 3D-U/S scans generated using the integrated U/S device. In the scientific stream Dr. Boris Hadaschik presented the first study on stereotactic navigated prostate biopsy using BiopSee® with truly impressive results.



NaviSuite 5.1 Released

A new major release of our Ultrasound based navigation software NaviSuite® has been issued. This version, introduced on Esaote's My-Lab Twice, incorporates new modules, enabling guided biopsies or RF treatments and a new 3D panoramic mode to combine multiple 3D US scans into one compound 3D dataset.




Picture kindly provided by Nucletron

"ProSoma User Meeting" in Birmingham, Dec. 2nd-3rd, 2010

The 3rd ProSoma UK User Meeting was staged in Birmingham, Dec. 2nd and 3rd by our partner and UK distributor OSL Ltd. MedCom took the chance to discuss future developments with the customers, collecting requests and recommendations for the upcoming ProSoma releases. MedCom team would like to thank OSL for their perfect event preparation enabling a successful user meeting.

VeriSuite is enlarging its impact

More and more proton therapy centers all over the world employ MedCom's VeriSuite® Patient Position Verification system in clinical operation: The first routine application was in the "ProCure Center" in Oklahoma City in 2009. Short time later followed "Roberts Proton Therapy Center" located in Philadelphia, the "Centre de Protontherapie d'Orsay" in France, the "ProCure Center" in Illinois and the "Hampton University Proton Therapy Center" in Virginia are all in clinical routine operation. Other centers such as the "National Cancer Center" in Kashiwa/Japan, the "WPE" in Essen/Germany, "CNAO" in Pavia/Italy and "PSI" in Switzerland are in the commissioning phase getting ready to start clinical operations with VeriSuite®. In one word, the internationally patented VeriSuite® system is by far the world-leader for patient verification in proton and heavy ion centers.



Two CT image series for patient positioning

left image: uncorrected position - overlay of planning and positioning scan in the upper row.

right image: registered CT data for a corrected positioning.

Oncentra Prostate v4.0 Released

MedCom GmbH released in cooperation with Pi Medical Ltd the new generation of Oncentra® Prostate, distributed worldwide by the global player Nucletron B.V. This new version is the first planning system available for prostate brachytherapy supporting both permanent (LDR) seeds and temporary implants (HDR/PDR). Highly sophisticated tools are now available for both treatment modalities guiding the user through planning and treatment process: protocol driven advanced optimization and evaluation methods enabling the user in planning and fulfilling individually defined treatment requirements. A paramount improvement is the "first-of-the-kind" availability of an ultrasound device integrated within the laptop cart, including a custom-made, dedicated transrectal BiopSee® transducer optimized for prostate treatment. The ultrasound device is controlled directly through Oncentra®, thus enabling seamless integration in clinical workflow: Linked to the new Nucletron laptop cart system - designed exclusively for Oncentra® Prostate - this results in a compact, ergonomic and highly mobile platform that proves itself in daily clinical routine.

We are excited by the acceptance by the customers and honored by their trust to our technology.

The roadmap of the VeriSuite development continues

The latest extensions of the VeriSuite® Patient Position Verification system support the real-time monitoring and verification of the patient during a fluoroscopy and respiratory gating treatment. Furthermore, the capabilities were extended by seamless integration of an automatic 3D/3D alignment procedure matching a pre-operative planning CT with an intra-operative positioning CT acquired directly within the treatment room (e.g. by CBCT). Last, we improved the support for standard oncology information systems in radiotherapy (ARIA, MOSAIQ) in order to ensure their seamless data transfer with VeriSuite®. VeriSuite® is the only system on the market offering each one of the above features.